Bendamustin (B) and rituximab (R) in the treatment of relapsed indolent CD 20+ non-Hodgkin-lymphoma - A phase II study of The East German Study Group of haematology and oncology (OSHO # 072)

被引：0
|
作者：
Lakner, V. [1 ]
Eschenburg, H. [1 ]
Aldaoud, A. [1 ]
Uhlig, J. [1 ]
机构：
[1] Praxis, Leipzig, Germany
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：209 / 210
页数：2
相关论文
共 50 条
  • [1] BENDAMUSTIN (B) AND RITUXIMAB (R) IN THE TREATMENT OF RELAPSED INDOLENT CD20+ NON-HODGKIN-LYMPHOMA - A PHASE II STUDY OF THE EAST GERMAN STUDY GROUP OF HAEMATOLOGY AND ONCOLOGY (OSHO #072)
    Lakner, V.
    Eschenburg, H.
    Schwarzer, A.
    Uhlig, J.
    Mohren, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 186 - 187
  • [2] Bendamustin in combination with Fludarabin for the treatment of refractory or relapsed low-grade lymphoma - A multicenter phase I/II trial of the East German study group for hematology and oncology (OSHO).
    Koenigsmann, MP
    Knauf, WU
    Herold, M
    Franke, A
    BLOOD, 2001, 98 (11) : 607A - 607A
  • [3] A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
    Chen, Robert
    Frankel, Paul
    Popplewell, Leslie
    Siddiqi, Tanya
    Ruel, Nora
    Rotter, Arnold
    Thomas, Sandra H.
    Mott, Michelle
    Nathwani, Nitya
    Htut, Myo
    Nademanee, Auayporn
    Forman, Stephen J.
    Kirschbaum, Mark
    HAEMATOLOGICA, 2015, 100 (03) : 357 - 362
  • [4] Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
    Tobinai, Kensei
    Ishizawa, Ken-ichi
    Ogura, Michinori
    Itoh, Kuniaki
    Morishima, Yasuo
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Watanabe, Takashi
    Yamamoto, Joji
    Uchida, Toshiki
    Nakata, Masanobu
    Terauchi, Takashi
    Nawano, Shigeru
    Matsusako, Masaki
    Hayashi, Masaki
    Hotta, Tomomitsu
    CANCER SCIENCE, 2009, 100 (10) : 1951 - 1956
  • [5] Rituximab maintenenance therapy in CD20+B-cell non-Hodgkin-lymphoma -: First interim results of a prospective randomised phase II study
    Witzens-Harig, M
    Hensel, M
    Schmier, J
    Neben, K
    Benner, A
    Krämer, A
    Ho, A
    ANNALS OF ONCOLOGY, 2005, 16 : 155 - 155
  • [6] Rituximab maintenenance therapy in CD20+B-cell Non-Hodgkin-Lymphoma - Final results of a multicenter prospective randomised phase II study
    Witzens-Harig, M.
    Benner, A.
    Rieger, M.
    McClanahan, F.
    Hensel, M.
    Neben, K.
    Dreger, P.
    Lengfelder, E.
    Schmidt-Wolf, I
    Kraemer, A.
    Ho, A.
    ONKOLOGIE, 2010, 33 : 204 - 204
  • [7] Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated:: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
    Rehwald, U
    Schulz, H
    Reiser, M
    Sieber, M
    Staak, JO
    Morschhauser, F
    Driessen, C
    Rüdiger, T
    Müller-Hermelink, K
    Diehl, V
    Engert, A
    BLOOD, 2003, 101 (02) : 420 - 424
  • [8] Phase-II trial of rituximab in patients with relapsed CD20-positive Hodgkin's lymphoma: An update from the German Hodgkin's Lymphoma Study Group (GHSG).
    Schulz, H
    Rehwald, U
    Reiser, M
    Ruediger, T
    Morschhauser, F
    Diehl, V
    Engert, A
    BLOOD, 2002, 100 (11) : 775A - 775A
  • [9] Risk-adapted high-dose therapy including autologous and allogeneic stem cell transplantation for relapsed or aggressive non-Hodgkin's lymphoma - a phase II trial by the OSHO (East German Study Group for Haematology and Oncology)
    Koenigsmann, M.
    Kahl, C.
    Freund, M.
    Basara, N.
    Niederwieser, D.
    Sayer, H.
    Theurich, S.
    Christopeit, M.
    Behre, G.
    Mohren, M.
    Franke, A.
    Reichle, A.
    Ganser, A.
    Metzner, B.
    Uharek, L.
    Balleisen, L.
    Hinke, A.
    Hinke, R.
    Casper, J.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S253 - S253
  • [10] Rituximab maintenenance therapy in CD20+ B-cell Non-Hodgkin-Lymphoma first results of a multicenter prospective randomised phase II study
    Witzens-Harig, M.
    Hensel, M.
    Schmier, J.
    Neben, K.
    Benner, A.
    Dreger, P.
    Kuhn, C.
    Schmidt-Wolf, I.
    Kramer, A.
    Ho, A. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 108 - 108
12345